Nektar Therapeutics (NKTR) Return on Capital Employed (2011 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Return on Capital Employed of 29.0% for Q1 2026, up 2566.0% year-over-year from 1.09% in Q1 2025, and up 50.86% quarter-over-quarter from 59.03% in Q4 2025.
Nektar Therapeutics (NKTR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Nektar Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 29.0% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 2566.0% year-over-year to 29.0%; the TTM figure through Mar 2026 stood at 29.0% (up 2566.0% YoY), while the FY2025 annual figure was 58.72%, down 2239.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 29.0%, up from 59.03% in the prior quarter.
- The five-year high for Return on Capital Employed was 29.0% in Q1 2026, with the low at 71.48% in Q4 2023.
- The 5-year median for Return on Capital Employed is 59.03% (2025), against an average of 55.88%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed plunged 2539 bps in 2022, then jumped 2846 bps in 2024.
- Nektar Therapeutics' Return on Capital Employed stood at 55.51% in 2022, then fell by 29 bps to 71.48% in 2023, then soared by 40 bps to 43.02% in 2024, then plunged by 37 bps to 59.03% in 2025, then surged by 51 bps to 29.0% in 2026.
- Business Quant data shows NKTR's Return on Capital Employed at 29.0% in Q1 2026, 59.03% in Q4 2025, and 52.15% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -29.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.00% |
| Dec 31, 2025 | -59.03% |
| Sep 30, 2025 | -52.15% |
| Jun 30, 2025 | -62.78% |
| Mar 31, 2025 | -54.66% |
| Dec 31, 2024 | -43.02% |
| Sep 30, 2024 | -59.31% |
| Jun 30, 2024 | -52.37% |
| Mar 31, 2024 | -47.71% |
| Dec 31, 2023 | -71.48% |
| Sep 30, 2023 | -67.92% |
| Jun 30, 2023 | -61.19% |
| Mar 31, 2023 | -68.42% |
| Dec 31, 2022 | -55.51% |
| Sep 30, 2022 | -59.20% |
| Jun 30, 2022 | -59.17% |
| Mar 31, 2022 | -46.95% |
| Dec 31, 2021 | -40.12% |
| Sep 30, 2021 | -37.48% |
| Jun 30, 2021 | -33.78% |